Literature DB >> 17646415

Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.

Thomas P Lodise1, Nimish Patel, Andrea Kwa, Jeffrey Graves, Jon P Furuno, Eileen Graffunder, Ben Lomaestro, Jessina C McGregor.   

Abstract

Although a growing number of studies have found a relationship between delayed appropriate antibiotic therapy and mortality, few have attempted to quantify the temporal association between delayed appropriate antibiotic therapy and mortality. This study was designed to measure the elapsed time associated with an increased risk of 30-day mortality among patients with Pseudomonas aeruginosa bacteremia. The retrospective cohort study was conducted among immunocompetent, adult patients with P. aeruginosa bacteremia onset at least 2 days after hospital admission between 1 January 2001 and 30 September 2006. Classification and regression tree analysis (CART) was used to identify the delay in appropriate antibiotic therapy that was associated with an increased risk of 30-day mortality. During the study period, 100 patients met the inclusion criteria. The CART-derived breakpoint between early and delayed treatment was 52 h. The delayed treatment group experienced a >2-fold significant increase in 30-day mortality compared to the early treatment group (44 and 19%, respectively, P = 0.008). Delayed appropriate therapy of >52 h (odds ratio [OR] = 4.1; 95% confidence interval [CI] 1.2 to 13.9, P = 0.03) was independently associated with 30-day mortality in the multivariate analysis. Antibiotic resistance > or =3 classes (adjusted OR [AOR] = 4.6; 95% CI = 1.9 to 11.2, P = 0.001) and chronic obstructive pulmonary disease (AOR = 5.4; 95% CI = 1.5 to 19.7, P = 0.01) were independently associated with delayed appropriate therapy of >52 h. The data strongly suggest that delaying appropriate therapy for approximately 2 days significantly increases the risk of 30-day mortality in patients with P. aeruginosa bloodstream infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646415      PMCID: PMC2043259          DOI: 10.1128/AAC.00338-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial.

Authors:  Rodger D MacArthur; Mark Miller; Timothy Albertson; Edward Panacek; David Johnson; Leah Teoh; William Barchuk
Journal:  Clin Infect Dis       Date:  2003-12-22       Impact factor: 9.079

2.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

3.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

4.  Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia.

Authors:  Regina B Osih; Jessina C McGregor; Shayna E Rich; Anita C Moore; Jon P Furuno; Eli N Perencevich; Anthony D Harris
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

5.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.

Authors:  E H Ibrahim; G Sherman; S Ward; V J Fraser; M H Kollef
Journal:  Chest       Date:  2000-07       Impact factor: 9.410

6.  Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.

Authors:  F Vidal; J Mensa; M Almela; J A Martínez; F Marco; C Casals; J M Gatell; E Soriano; M T Jimenez de Anta
Journal:  Arch Intern Med       Date:  1996-10-14

7.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

8.  The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.

Authors:  L Leibovici; I Shraga; M Drucker; H Konigsberger; Z Samra; S D Pitlik
Journal:  J Intern Med       Date:  1998-11       Impact factor: 8.989

9.  Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia.

Authors:  Thomas P Lodise; Peggy S McKinnon; Linda Swiderski; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2003-05-20       Impact factor: 9.079

10.  Pseudomonas bacteremia. Retrospective analysis of 410 episodes.

Authors:  G P Bodey; L Jadeja; L Elting
Journal:  Arch Intern Med       Date:  1985-09
View more
  83 in total

Review 1.  The multiple signaling systems regulating virulence in Pseudomonas aeruginosa.

Authors:  Pol Nadal Jimenez; Gudrun Koch; Jessica A Thompson; Karina B Xavier; Robbert H Cool; Wim J Quax
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

2.  Rapid identification of bacteria from positive blood culture bottles by use of matrix-assisted laser desorption-ionization time of flight mass spectrometry fingerprinting.

Authors:  Martin Christner; Holger Rohde; Manuel Wolters; Ingo Sobottka; Karl Wegscheider; Martin Aepfelbacher
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

3.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

4.  Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.

Authors:  Enrico Maria Trecarichi; Mario Tumbarello; Morena Caira; Anna Candoni; Chiara Cattaneo; Domenico Pastore; Rosa Fanci; Annamaria Nosari; Nicola Vianelli; Alessandro Busca; Antonio Spadea; Livio Pagano
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

5.  Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.

Authors:  John S Esterly; Jamie Wagner; Milena M McLaughlin; Michael J Postelnick; Chao Qi; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

6.  In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Authors:  A Walkty; M DeCorby; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 7.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

8.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

9.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

10.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.

Authors:  A J Kaasch; S Rieg; J Kuetscher; H-R Brodt; T Widmann; M Herrmann; C Meyer; T Welte; P Kern; U Haars; S Reuter; I Hübner; R Strauss; B Sinha; F M Brunkhorst; M Hellmich; G Fätkenheuer; W V Kern; H Seifert
Journal:  Infection       Date:  2013-03-29       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.